Anti-Viral Therapies Market by Type (Generic Drugs and Branded Drugs), Application (HIV, Hepatitis, Herpes Virus, Influenza, and Other Applications), and Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2026
- ALL3931786
- 238 Pages
- May 2020
- Medical Devices
The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products, are expected to fuel the market growth. However, high cost involved in the treatment and rise in demand for alternative medicines such as naturopathy and homeopathy are likely to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to provide numerous opportunities for the market growth during the forecast period.
The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. By mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Application
• HIV
• Hepatitis
• Herpes Virus
• Influenza
• Other Applications
By Type
• Generic Drugs
• Branded Drugs
By Mechanism of Action
• Nucleotide Polymerase Inhibitor
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o Spain
o Italy
o UK
o Rest of Europe
• Asia-Pacific
o Japan
o India
o China
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, GlaxoSmithKline
• Bristol-Myers-Squibb
• Abbott Laboratories
• AstraZeneca plc
• AbbVie Inc.
• Aurobindo Pharma Limited
• Johnson & Johnson
• Merck & Co., Inc
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Market dynamics
3.3.1.Drivers
3.3.1.1.Surge in global burden of viral infection
3.3.1.2.Stronger pipeline of anti-viral drugs
3.3.2.Restraints
3.3.2.1.Higher cost of treatment
3.3.3.Opportunities
3.3.3.1.Increase in number of product approvals for combination therapy
CHAPTER 4:ANTI-VIRAL THERAPIES MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.HIV
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Hepatitis
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Herpes virus
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Influenza
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Other Applications
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
CHAPTER 5:ANTI-VIRAL THERAPIES MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Generic drugs
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Branded drugs
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
CHAPTER 6:ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION
6.1.Overview
6.1.1.Market size and forecast
6.2.Nucleotide polymerase inhibitor
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Reverse transcriptase inhibitors
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Protease inhibitors
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
6.5.Others
6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country
CHAPTER 7:GLOBAL ANTI-VIRAL THERAPIES MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by type
7.2.3.Market size and forecast, by mechanism of action
7.2.4.Market size and forecast, by application
7.2.5.Market size and forecast, by country
7.2.5.1.U.S. market size and forecast, by type
7.2.5.2.U.S. Market size and forecast, by mechanism of action
7.2.5.3.U.S. market size and forecast, by application
7.2.5.4.Canada market size and forecast, by type
7.2.5.5.Canada Market size and forecast, by mechanism of action
7.2.5.6.Canada market size and forecast, by application
7.2.5.7.Mexico market size and forecast, by type
7.2.5.8.Mexico Market size and forecast, by mechanism of action
7.2.5.9.Mexico market size and forecast, by application
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by type
7.3.3.Market size and forecast, by mechanism of action
7.3.4.Market size and forecast, by application
7.3.5.Market size and forecast, by country
7.3.5.1.Germany market size and forecast, by type
7.3.5.2.Germany Market size and forecast, by mechanism of action
7.3.5.3.Germany market size and forecast, by application
7.3.5.4.France market size and forecast, by type
7.3.5.5.France Market size and forecast, by mechanism of action
7.3.5.6.France market size and forecast, by application
7.3.5.7.UK market size and forecast, by type
7.3.5.8.UK Market size and forecast, by mechanism of action
7.3.5.9.UK market size and forecast, by application
7.3.5.10.Italy market size and forecast, by type
7.3.5.11.Italy Market size and forecast, by mechanism of action
7.3.5.12.Italy market size and forecast, by application
7.3.5.13.Spain market size and forecast, by type
7.3.5.14.Spain Market size and forecast, by mechanism of action
7.3.5.15.Spain market size and forecast, by application
7.3.5.16.Rest of Europe market size and forecast, by type
7.3.5.17.Rest of Europe Market size and forecast, by mechanism of action
7.3.5.18.Rest of Europe market size and forecast, by application
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by type
7.4.3.Market size and forecast, by mechanism of action
7.4.4.Market size and forecast, by application
7.4.5.Market size and forecast, by country
7.4.5.1.Japan market size and forecast, by type
7.4.5.2.Japan Market size and forecast, by mechanism of action
7.4.5.3.Japan market size and forecast, by application
7.4.5.4.China market size and forecast, by type
7.4.5.5.China Market size and forecast, by mechanism of action
7.4.5.6.China market size and forecast, by application
7.4.5.7.India market size and forecast, by type
7.4.5.8.India Market size and forecast, by mechanism of action
7.4.5.9.India market size and forecast, by application
7.4.5.10.Australia market size and forecast, by type
7.4.5.11.Australia Market size and forecast, by mechanism of action
7.4.5.12.Australia market size and forecast, by application
7.4.5.13.South Korea market size and forecast, by type
7.4.5.14.South Korea Market size and forecast, by mechanism of action
7.4.5.15.South Korea market size and forecast, by application
7.4.5.16.Rest of Asia-Pacific market size and forecast, by type
7.4.5.17.Rest of Asia-Pacific Market size and forecast, by mechanism of action
7.4.5.18.Rest of Asia-Pacific market size and forecast, by application
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by type
7.5.3.Market size and forecast, by mechanism of action
7.5.4.Market size and forecast, by application
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil market size and forecast, by type
7.5.5.2.Brazil Market size and forecast, by mechanism of action
7.5.5.3.Brazil market size and forecast, by application
7.5.5.4.Saudi market size and forecast, by type
7.5.5.5.Saudi Market size and forecast, by mechanism of action
7.5.5.6.Saudi market size and forecast, by application
7.5.5.7.South Africa market size and forecast, by type
7.5.5.8.South Africa Market size and forecast, by mechanism of action
7.5.5.9.South Africa market size and forecast, by application
7.5.5.10.Rest of LAMEA market size and forecast, by type
7.5.5.11.Rest of LAMEA Market size and forecast, by mechanism of action
7.5.5.12.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
8.1.Abbott Laboratories
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.AbbVie Inc.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance
8.2.5.Key strategic moves and developments
8.3.Bristol Myers Squibb Company
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.F. Hoffmann-La Roche Ltd.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Johnson & Johnson
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Business performance
8.6.Merck & Co., Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Business performance
8.6.5.Key strategic moves and developments
8.7.GILEAD SCIENCES, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.GlaxoSmithKline Plc.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.AstraZeneca PLC
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Aurobindo Pharma Limited
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
TABLE 01.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 02.HIV ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 03.HEPATITIS ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 04.HERPES VIRUS ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 05.INFLUENZA ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 06.OTHER APPLICATIONS ANTI VIRAL THERAPIES MARKET BY REGION, 2018–2026 ($MILLION)
TABLE 07.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 08.ANTI-VIRAL THERAPIES MARKET FOR GENERIC DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 09.ANTI-VIRAL THERAPIES MARKET FOR BRANDED DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 10.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION, 2018–2026 ($MILLION)
TABLE 11.ANTI-VIRAL THERAPIES MARKET, FOR NUCLEOTIDE POLYMERASE INHIBITOR, BY REGION, 2018–2026 ($MILLION)
TABLE 12.ANTI-VIRAL THERAPIES MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 13.ANTI-VIRAL THERAPIES MARKET FOR PROTEASE INHIBITORS, BY REGION, 2018–2026 ($MILLION)
TABLE 14.ANTI-VIRAL THERAPIES MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 15.GLOBAL ANTI-VIRAL THERAPIES MARKET BY REGION, 2018-2026, ($MILLION)
TABLE 16.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 17.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 18.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 19.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 20.U.S. ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 21.U.S. ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 22.U.S. ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 23.CANADA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 24.CANADA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 25.CANADA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 26.MEXICO ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 27.MEXICO ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 28.MEXICO ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 29.EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 30.EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 31.EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 32.EUROPE ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 33.GERMANY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 34.GERMANY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 35.GERMANY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 36.FRANCE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 37.FRANCE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 38.FRANCE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 39.UK ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 40.UK ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 41.UK ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 42.ITALY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 43.ITALY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 44.ITALY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 45.SPAIN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 46.SPAIN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 47.SPAIN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 48.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 49.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 50.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 51.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 52.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 53.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 54.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 55.JAPAN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 56.JAPAN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 57.JAPAN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 58.CHINA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 59.CHINA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 60.CHINA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 61.INDIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 62.INDIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 63.INDIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 64.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 65.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 66.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 67.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 68.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 69.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 73.LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 74.LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 75.LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 76.LAMEA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 77.BRAZIL ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 78.BRAZIL ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 79.BRAZIL ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 80.SAUDI ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 81.SAUDI ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 82.SAUDI ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 83.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 84.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 85.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 86.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
TABLE 87.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
TABLE 88.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 89.ABBOTT: COMPANY SNAPSHOT
TABLE 90.ABBOTT: OPERATING SEGMENTS
TABLE 91.ABBOTT: PRODUCT PORTFOLIO
TABLE 92.ABBVIE: COMPANY SNAPSHOT
TABLE 93.ABBVIE: OPERATING SEGMENTS
TABLE 94.BMS: COMPANY SNAPSHOT
TABLE 95.BMS: OPERATING SEGMENTS
TABLE 96.BMS: PRODUCT PORTFOLIO
TABLE 97.ROCHE: COMPANY SNAPSHOT
TABLE 98.ROCHE: OPERATING SEGMENTS
TABLE 99.ROCHE: PRODUCT PORTFOLIO
TABLE 100.J&J: COMPANY SNAPSHOT
TABLE 101.J&J: OPERATING SEGMENTS
TABLE 102.MERCK: COMPANY SNAPSHOT
TABLE 103.MERCK: OPERATING SEGMENTS
TABLE 104.GILEAD: COMPANY SNAPSHOT
TABLE 105.GILEAD: OPERATING SEGMENTS
TABLE 106.GILEAD: PRODUCT PORTFOLIO
TABLE 107.GSK.: COMPANY SNAPSHOT
TABLE 108.GSK: OPERATING SEGMENTS
TABLE 109.GSK: PRODUCT PORTFOLIO
TABLE 110.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 111.ASTRAZENECA: OPERATING SEGMENTS
TABLE 112.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 113.AUROBINDO: COMPANY SNAPSHOT
TABLE 114.AUROBINDO: OPERATING SEGMENTS
TABLE 115.AUROBINDO: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
